

# ***Diffuse Parenchymal Lung Disease***

## ***ACOI Board Review 2017***

**Thomas F. Morley, DO, FACOI, FCCP, FAASM**  
**Professor of Medicine**  
**Chairman Department of Internal Medicine**  
**Director of the Division of Pulmonary, Critical  
Care and Sleep Medicine**  
**Rowan University - SOM**

***No Disclosures***


# ***Restrictive Lung Diseases***

## ***By Category***

- 1. Lung Fibrosis**
- 2. Thoracic Deformity**
- 3. Massive effusion**
- 4. Respiratory muscle weakness**
- 5. Increased abdominal pressure**
- 6. Extrinsic Compression**

# ***ILD = Misnomer***

- **Most of these disease are not restricted to the “interstium” of the lung**
- **It is actually a radiographic term to differentiate it from alveolar filling diseases**
- **Diffuse Parenchymal Lung Disease is a better term**



**The interstitium is the scant space between the capillary endothelial cell and the lung epithelium. It also includes the space that airways, blood vessel, and lymphatics traverse.**

# ***Interstitial Lung Disease***

## ***Characteristics***

- 1. Diffuse infiltrates bilaterally**
- 2. Restrictive Physiology**
- 3. Histologic distortion of gas exchange areas**
- 4. Dyspnea (exercise desat) and cough**

# ***Differential Diagnosis of DPLD***

## **COMMON**

**Sarcoidosis**

**IPF (aka cryptogenic  
fibrosing alveolitis**

**BOOP**

**Lymphangetic Spread of CA**

**Pneumoconiosis**

**Drug-induced**

**Chronic Eosinophilic Pneumonia**

## **LESS COMMON**

**Langerhans Cell Granulomatosis  
(aka, EG, histiocytosis X**

**Hypersensitivity Pneumonitis**


**Collagen Vascular Diseases  
(RA, SLE, MCTD, PSS)**

**Granulomatous vasculitis**

**Goodpasture's syndrome**

**Alveolar proteinosis**

# Pathogenesis of Interstitial Lung Diseases





# Approach to DPLD

## Slide 1

### 1. Characteristics of Presenting Illness

Duration of Symptoms

Rate of Progression

Fever

Hemoptysis

Extrathoracic manifestations

### 2. Exposures

Pneumoconiosis

Hypersensitivity

Drug-induced

Occupational

IV drug use

# Approach to DPLD

## Slide 2

<b>3. Physical Exam</b>	<b>Crackles</b>
<b>Thoracic</b>	<b>Wheeze</b>
	<b>Rub</b>
	<b>Normal</b>
<b>Extrathoracic</b>	<b>Nodes</b>
	<b>Skin</b>
	<b>Joints</b>
	<b>CNS</b>
	<b>Eyes</b>

# ***Approach to DPLD***

## ***Slide 3***

### **4. Laboratory (All)**

**CBC with Diff**

**UA/Creatinine**

**CRP, RF, ANA**

**ACE level**

### **If H+P Suggestive:**

**ANCA-c (granulomatosis  
with polyangitis)**

**RNP (MCTD)**

**Anti-GBM (Goodpasture's)**



# ***Serologic Tests Can Help Exclude Other Conditions***

Connective tissue diseases

CRP  
ANA  
CCP (for RA) Cyclic Citrullinated Peptide Antibody  
CK  
Aldolase  
Anti-myositis panel with Jo-1 antibody  
ENA panel

- Scl-70 – SSc (topoisomerase I)
- Ro (SSA) - Sjogrens
- La (SSB)
- Smith -Lupus
- RNP - MCTD

Hypersensitivity pneumonitis

Hypersensitivity panel  
(if exposure history)

# Approach to DPLD

## Slide 4

		Adenopathy	Nodules
<b>5. X-Ray Patterns</b>	<b>Reticular</b> <b>Reticulonodular</b> <b>Nodular</b> <b>Ground Glass</b>	<b>Sarcoidosis</b> <b>Silicosis</b> <b>Berylliosis</b> <b>Langerhans cell granulomatosis</b>	<b>Sarcoidosis</b> <b>Rheumatoid Arthritis</b> <b>Wegener's</b> <b>SLE</b> <b>Sjogren's</b>
<b>Distribution</b>			
<b>Upper Lobe</b>	<b>Silicosis</b> <b>Sarcoidosis</b> <b>Langerhans Cell Gran.</b> <b>Ankylosing spondylitis</b>	<b>Pleural</b>	<b>Asbestos</b> <b>RA</b> <b>SLE</b>
<b>Lower Lobe</b>	<b>IPF</b> <b>Rheumatoid arthritis</b> <b>Asbestosis</b> <b>PSS</b> <b>Sjogren's</b>		

# ***Approach to DPLD***

## ***Slide 5***

<b>6. PFT</b>	<b>Spirometry</b> <b>Lung volumes</b> <b>DLCO</b> <b>ABG</b>
<b>7. Tissue</b>	<b>Transbronchial Biopsy</b> <b>Thoracoscopy</b> <b>Open lung biopsy</b> <b>Extrathoracic sites</b>
<b>BAL ?</b>	
<b>Gallium Scan ?</b>	

# ***Symptom Duration in DPLD***

<b>Chronic</b>	<b>Acute/Subacute</b>
<b>IPF</b>	<b>BOOP</b>
<b>Rheumatoid Lung</b>	<b>Drug-induced</b>
<b>Sarcoidosis</b>	<b>Hypersensitivity</b>
<b>Langerhans Cell Granulomatosis</b>	<b>Chemical exposure</b>
<b>Pneumoconiosis</b>	



# ***Extrathoracic Manifestations of DPLD (1)***

**Nasal symptoms**

**Arthritis**

**Skin**

**Wegener's Granulomatosis**

**RA**

**Sarcoidosis**

**CVD**

**Granulomatous vasculitis**

**Sjogren's syndrome**

**Sarcoidosis**

**CVD**

**Granulomatous vasculitis**

**Dermatomyositis**

**PSS**



# ***Extrathoracic Manifestations of DPLD (2)***

<b>CNS</b>	<b>CVD</b> <b>Sarcoidosis</b> <b>Lymphomatoid granulomatosis</b>
<b>Muscle</b>	<b>Sarcoidosis</b> <b>Polymyositis</b>
<b>GI</b>	<b>PSS</b> <b>Polymyositis</b>
<b>Renal</b>	<b>Wegener's granulomatosis</b> <b>CVD</b> <b>Goodpasture's</b> <b>PSS</b>

# **CASE 1**

- **34 y.o. black, female presents with 6 months of non-productive COUGH, and DYSPNEA with exertion**
- **NO MEDS or IVDA**
- **NO OCCUPATIONAL EXPOSURES**
- **NO SYSTEMIC SIGNS OR SYMPTOMS**

# Sarcoidosis

## X-ray Findings at Presentation


<b>STAGE</b>	<b>FINDINGS</b>	<b>PERCENT</b>
<b>O</b>	<b>Normal</b>	<b>5</b>
<b>I</b>	<b>BHA</b>	<b>50</b>
<b>II</b>	<b>BHA + Lung</b>	<b>30</b>
<b>III</b>	<b>Lung Only</b>	<b>15</b>
<b>IV</b>	<b>Fibrosis</b>	




***BHA: Sarcoidosis***

**35 yo  
male**

**Sarcoidosis**




***Stage 2 sarcoidosis  
pre-tx***



***Stage 2 sarcoidosis***


***2 years post-tx***



**Adult  
female**

**Nodular  
Sarcoidosis**

**Stage 3**






# ***Sarcoidosis***

- **Multisystem disease of unknown etiology**  
**Noncaseating granuloma are characteristic**  
**NOT DIAGNOSTIC**
- **Lung is the most common organ system involved (94%)**
- **Peak onset 2nd and 3rd decades**
- **10 to 17 times more prevalent in blacks**

# *Sarcoidosis*

- Gallium scan does NOT correlate with need for or response to TX.
- LAB: ACE, LFT's, Calcium, UA hypergammaglobulinemia (68 %)
- Anergy (43 to 66 %)
- Dx: Transbronchial lung biopsy (TBLBx) is adequate for Dx 80 to 90 %.  
BAL - lymphocytic
- Tx: Steroids

# ***Noncaseating Granulomas***



# ***Diagnosis of Sarcoidosis***

## ***THREE ELEMENTS***

- 1. Compatible clinical picture**
- 2. Noncaseating granulomas in tissue**
- 3. Negative culture/stains for AFB and fungi**

# CASE 2


- 60 y.o. white, male severe exertional dyspnea over 3 to 4 years. Non-productive cough is noted.
- Viral prodrome prior to initial symptoms.
- Nonsmoker, no meds, no occupational exposures, No high risk behaviors
- EXAM - Crackles, digital clubbing

# ***Idiopathic Pulmonary Fibrosis*** ***AKA Cryptogenic Fibrosing Alveolitis***


- **Older age (> 60 Y.O.), M sl > F**
- **Slow progression over 2 or more years.**
- **Non-productive cough, dyspnea**
- **Clubbing 50-90 % of patients**

# US Demographics of IPF

## Incidence



## Prevalence



- Incidence: > 30,000 patients/year
- Prevalence: > 80,000 current patients
- Age of onset: most 40–70 years
- Two-thirds > 60 years old at presentation
- Males > females

ATS/ERS. *Am J Respir Crit Care Med.* 2000;161:646-664.

Raghu G, et al. *Am J Respir Crit Care Med.* 2006;174:810-816.

# Idiopathic Pulmonary Fibrosis

**IPF**







The surface of the lung of an IPF patient showing advanced honeycombing



# *Tx for IPF*

**50 % mortality at 5 years**

**10 % develop bronchogenic CA**

**Nintedanib, (OFEV) a receptor blocker for multiple tyrosine kinases that mediate elaboration of fibrogenic growth factors**

**Pirfenidone (Espiert) is an antifibrotic agent that inhibits transforming growth factor beta (TGF- $\beta$ )-stimulated collagen synthesis, decreases the extracellular matrix, and blocks fibroblast proliferation in vitro**

**Transplant**


# ***Idiopathic Pulmonary Fibrosis***

## ***Diagnosis***

- **X-ray shows bilateral reticular or reticulonodular infiltrates with lower lobe distribution**
- **HRCT -subpleural septal thickening**
- **Lab: non-specific**
- **Classically Open lung biopsy is required for definitive diagnosis**

# ***Current Definition of IPF***

- **Distinct chronic fibrosing interstitial pneumonia**
- **Unknown cause**
- **Limited to the lungs**
- **Has typical HRCT findings**
- **Associated with a histologic pattern of UIP**



ATS/ERS Consensus Statement. *Am J Respir Crit Care Med.* 2002;165:277-304.



School of  
Osteopathic Medicine


# Diagnostic Criteria for IPF Without a Surgical Lung Biopsy

Major Criteria	Minor Criteria
<ul style="list-style-type: none"><li>• Exclusion of other known causes of ILD</li></ul>	<ul style="list-style-type: none"><li>• Age &gt; 50 years</li></ul>
<ul style="list-style-type: none"><li>• Evidence of restriction and/or impaired gas exchange</li></ul>	<ul style="list-style-type: none"><li>• Insidious onset of otherwise unexplained dyspnea on exertion</li></ul>
<ul style="list-style-type: none"><li>• HRCT: bibasilar reticular abnormalities with minimal ground-glass opacities (honeycombing is characteristic*)</li></ul>	<ul style="list-style-type: none"><li>• Duration of illness &gt; 3 months</li></ul>
<ul style="list-style-type: none"><li>• TBB or BAL that does not support an alternative diagnosis</li></ul>	<ul style="list-style-type: none"><li>• Bibasilar, inspiratory, Velcro® crackles</li></ul>


- All major criteria and at least 3 minor criteria must be present to increase the likelihood of an IPF diagnosis
- Criteria currently under revision (2009)

\*Not included in current guidelines


ATS/ERS. *Am J Respir Crit Care Med*. 2000;161:646-664.



# ***IPF - H+E stain***



# ***IPF (trichrome stain)***






# CASE 3

- 43 y.o. white female presented with 2 months of fever, cough, dyspnea, and 12 lbs wt loss
- No meds, 20 P-Y smoker
- No occupational exposures
- No high risk behavior
- Exam: 100 temp, crackles upper lobes


# ***Chronic Eosinophilic Pneumonia***



# ***Chronic Eosinophilic Pneumonia***



# ***Chronic Eosinophilic Pneumonia***



[http://www.mevis-research.de/~hhj/Lunge/ima/inf\\_eos\\_thb99.JPG](http://www.mevis-research.de/~hhj/Lunge/ima/inf_eos_thb99.JPG)

# ***Chronic Eosinophilic Pneumonia***

- **Peak 3rd decade, 2:1 F:M**
- **Subacute presentation over months  
cough, fever, dyspnea, wt loss**
- **X-ray - bilateral upper lobe infiltrates  
PERIPHERAL distribution (esp HRCT)**
- **Blood, biopsy, BAL all with eosinophilia**
- **Dramatic improvement with steroids  
(maintain for 6 months)**

# ***Drug-induced Interstitial Lung Disease***

**Antirheumatics**

**Gold**

**Penicillamine**

**Methotrexate**

**Antineoplastics**

**Bleomycin**

**Cyclophosphamide**

**Mitomycin**

**Antiarrhythmics**

**Amiodarone**

**Radiation**

**Oxygen**

**Illicit Drugs**

**Talc**

**cocaine**

# ***Collagen Vascular Diseases with ILD***

**RA**


**PSS**

**Polymyositis/Dermatomyositis**

**MCTD**

**LUPUS**

**pulmonary  
fibrosis  
due to  
RA**






# **CASE 4**

- 47 y.o. homosexual male with 11 month Hx of non-productive cough, fever, sweats, wheezing**
- Also 35 lbs wt loss over 6 months**
- EXAM: fever, basilar crackles  
No clubbing**



**CT  
BOOP/COP**

**Subpleural**

**Ground  
glass  
infiltrates**



# ***Bronchiolitis Obliterans Organizing Pneumonia/COP***



# ***Bronchiolitis Obliterans-Organizing Pneumonia*** ***AKA Cryptogenic Organizing Pneumonia***

- Patient with patchy alveolar infiltrates who does not improve following antibiotics**
- 4th to 6th decade - subacute 2 -10 wk present**
- Fever, dry cough, following flu-like illness  
Myalgia, headache, malaise are common**
- X-ray shows bilateral infiltrates,  
10 % reticular  
Peripheral distribution on HRCT**

# ***Bronchiolitis Obliterans-Organizing Pneumonia*** ***COP***

---

- **Pathology**  
Intraluminal fibrosis with connective tissue plugs in the respiratory bronchioles, alveolar ducts, and alveoli
- **Open lung Bx - NOT NECESSARY**  
TBLBx and BAL are adequate
- **Steroid Responsive**  
3 to 6 months Tx  
Recurrence common if Tx stopped too early

# **CASE 5**

- **53 y.o. white male progressive dyspnea over 1 year. Some cough with yellow Sputum**
- **Heavy Smoker**
- **Occupation: tombstones engraver**
- **EXAM: decreased breath sounds digital clubbing**

**56 yo  
Male**

**Anthracosis  
PMF**



56 yo  
Male


Anthracosis  
PMF



School of  
Osteopathic Medicine



# ***Silicosis, PMF, Cavitation***






School of  
Osteopathic Medicine

# ***Egg shell calcification***





# ***Pneumoconiosis***

## ***Inhaled Inorganic Dusts***

---


- 1. Big Three  
Asbestosis, Anthracosis, Silicosis**
- 2. Long gap between exposure and symptoms  
from ILD**
- 3. Asbestos - Lower lobe reticular changes  
Parietal pleural plaques**
- 4. Anthracosis - Upper lobe nodules - PMF**
- 5. Silicosis - Upper lobe nodules - PMF  
Hilar adenopathy  
Egg shell calcification**

# Asbestos plaques



# Asbestos plaques





TY

c Medicine



# ***Hypersensitivity Pneumonitis***

---


- \* Caused by repeated inhalation of an ORGANIC dust or chemical - leads to sensitization**
- \* Symptoms may be acute or chronic**
- \* Fever, cough, dyspnea, and infiltrates occur 4 to 6 hrs post exposure  
Repeated exposure leads to fibrosis**
- \* Dx: depends on history and specific precipitating antibodies to the antigen**

# ***Hypersensitivity Pneumonitis***

---

- \* **Type III - immune complex injury and Type IV - delayed hypersensitivity is involved in pathology**
- \* **Acute pathology shows PMN infiltrate 3 days later the infiltrate becomes lymphocytic and loose granulomas form. FOAMY histiocytes and bronchiolitis obliterans may be noted**

# ***Hypersensitivity Pneumonitis***



# ***Langerhans Cell Granulomatosis***

## ***EG, HSC, and LS***


---

- **All 3 disorders share a common pathology**  
**Aggregations of abnormal histiocytes (Langerhan's cells)**
- **Lung and bone are most often affected with UNIFOCAL disease**
- **Multifocal disease - worse prognosis**

**26 yo  
male**

**Langerhans  
Cell  
Granulomatosis**

**Histiocytosis X**




26 yo  
male

LCG



*Langerhans  
Cell  
Granulomatosis*



# **LCG**

## ***CLINICAL FEATURES***

- 10 to 40 Y.O. M=F**
- Present with cough, fever, dyspnea, chest pain**
- 10 % present with pneumothorax**
- X-ray - upper lobe cystic and reticulonodular changes  
NO VOLUME LOSS**